'1-hit' event provides new opportunity for colon cancer prevention, say Fox Chase researchersSeptember 15, 2008More than 30 years ago, Alfred Knudson Jr., M.D., Ph.D., revolutionized the field of cancer genetics by showing that a person must lose both their paternal and maternal copies of a particular class of cancer-inhibiting genes, called tumor-suppressor genes, in order to develop cancer. This theory, called the two-hit hypothesis, guided scientists around the globe in their quest for tumor suppressor genes. Now Knudson, a Fox Chase Cancer Center Distinguished Scientist and senior advisor to the Center president, and colleagues offer evidence that a "one-hit" event is enough to change the cells and increase the likelihood they would become cancerous. By studying people who have inherited the first hit in every cell in the body, the Fox Chase researchers believe they may have discovered a source for some of the earliest known molecular changes that signal the presence of colorectal cancer, the second leading cause of cancer-related death in the United States. Their findings are presented in the September 15 issue of the journal Cancer Research. "We hypothesized that an inherited one-hit gene mutation can, by itself, lead to changes in the proteins of normal-looking cells" says Anthony Yeung, Ph.D., lead author of the paper and a tenured member of the Fox Chase scientific staff. "While these cells are just another hit away from becoming cancerous, their altered patterns of protein production may represent new biomarkers of cancer and novel targets for preventive and therapeutic drugs - a chance to strike at cancer before a second hit can happen."
The Fox Chase researchers studied patients with familial adenomatous polyposis (FAP), an inherited disorder that also serves as a classic model in support of the two-hit hypothesis. Patients with FAP, which predisposes people to colon cancer, carry mutations in one of their two copies of the adenomatous polyposis coli (APC) tumor-suppressor gene. The APC gene acts to prevent the colon cells from growing out of control and becoming cancerous. The APC gene is also mutated in most cases of sporadic colorectal cancer. According to Yeung, the proteome, the sum total of proteins a cell will create from the genome, offers an insight into the physical state of cells. "We see that a single hit, in this case an inherited mutation, can have many repercussions within the entire cell even if it doesn't cause cancer itself," Yeung says. "The 'one-hit' event makes a second mutation that much more likely to push the cell over the edge into cancer." This is the first time the human colon proteome has been characterized to this depth, made possible by samples of high quality and purity donated by research participants. Approximately 13 percent of 1,695 identified proteins were abnormally produced in the colon of APC mutation carriers, indicating that a colon cell under the one-hit state is already abnormal. Many of the changes affect molecular pathways consistent with the function of the APC protein as a tumor suppressor, including how the cell moves, interacts with other cells, divides, responds to free radical damage and, ultimately, self-destructs when growth threatens to go out of control. "The two-hit hypothesis is applicable to most cancers because there are hundreds of tumor-suppressor genes," Yeung says. "The knowledge acquired in this study on the proteome of precancerous one-hit cells could be an opportunity to devise rational strategies, based on drugs or dietary changes, that may delay a second hit from occurring and thus prevent cancer from happening entirely." Fox Chase Cancer Center | |||||||||||||||||||||
|
Related Colon Cancer Current Events and Colon Cancer News Articles Drop in cancer deaths tied primarily to gains in behavior and screening Improvements in behavior and screening have contributed greatly to the 13 percent decline in cancer mortality since 1990, with better cancer treatments playing a supporting role, according to new research from David Cutler of Harvard University. Combining targeted therapy drugs may treat previously resistant tumors A team of cancer researchers from several Boston academic medical centers has discovered a potential treatment for a group of tumors that have resisted previous targeted therapy approaches. A Simple Blood Test for Colon Cancer People are often reluctant to undergo a routine but painful colonoscopy ― but the consequences can be fatal. According to the American Cancer Society, colon cancer is the third most common cancer found in American men and women and kills about 50,000 Americans every year. Adalimumab may reduce health-care costs for Crohn's disease patients Inflammatory bowel disease (IBD) is a term that refers to both ulcerative colitis (UC) and Crohn's disease (CD). IBD occurs most frequently in people in their late teens and twenties. There have been cases in children as young as two years old and in older adults in their seventies and eighties; men and women have an equal chance of getting the disease. Washington University scientists first to sequence genome of cancer patient For the first time, scientists have decoded the complete DNA of a cancer patient and traced her disease - acute myelogenous leukemia - to its genetic roots. Minority patients discouraged from cancer screening by negative messages New behavioral science research published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research, found that constantly emphasizing the negative consequences of a lack of cancer screening among minorities can actually make them less likely to go for screening. Sibling study could lead to better treatments for inherited form of colon cancer Researchers at Huntsman Cancer Institute (HCI) believe they may be one step closer to understanding how certain forms of colon cancer develop. What's the role of beta-catenin in colorectal cancers? Beta-catenin, a central molecule of the Wnt-signaling pathway was previously known to involve in the tumorigenesis of various gastrointestinal cancers such as gastric cancer and colon cancer. Jefferson Department of Surgery announces new pancreas tumor registry Charles J. Yeo, M.D., Samuel D. Gross Professor and Chair, Department of Surgery at Jefferson Medical College of Thomas Jefferson University, announces the establishment of the new Jefferson Pancreas Tumor Registry (JPTR). Supercomputer provides massive computational boost to biomedical research at TGen In less time than the blink of an eye, the Translational Genomics Research Institute's new supercomputer at Arizona State University can do operations equal to every dollar in the recent Wall Street bailout. More Colon Cancer Current Events and Colon Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||